US4996225A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Tri-phenyl alkane derivatives and their oestrogenic, anti-oestrogenic and progestanic uses
Assignee: Orion Oyj
•
Filing: 1989-10-12
•
Granted: 1991-02-26
•
Expires: 2009-10-12
Abstract
Abstract ##STR1## wherein n is 0 to 4, R 1 and R 2 , which can be the same or different, are H or OH; R 3 is --O--(CH 2 ) m --CH 2 --NR 6 R 7 wherein m is 1 or 2, R 6 and R 7 , which can be the same or different, are H or an alkyl group of 1 to 4 carbon atoms, or --NR 6 R 7 can form a pyrrolidinyl group; and R 4 is halogen, and their non-toxic pharmaceutically acceptable salts and phenolic esters of aliphatic or aromatic carboxylic acids, acid anhydrides or acid chlorides thereof are disclosed. These compounds exhibit valuable pharmacological properties as estrogenic, anti-estrogenic, and progestanic agents. They show activity against oestrogen-dependent tumors.
Inventors
- 👤 Reijo J. Toivola
- 👤 Arto J. Karjalainen
- 👤 Kauko O. A. Kurkela
- 👤 Marja-Liisa Soderwall
- 👤 Lauri V. M. Kangas
- 👤 Guillermo L. Blanco
- 👤 Hannu K. Sundquist
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 08:05
CPC Classifications
C; C07; C07D; C07D295/00; C07D295/04; C07D295/08; C07D295/084; C07D295/088; C07C; C07C29/00; C07C29/09; C07C29/095; C07C29/10; C07C29/128; C07C29/1285; C07C309/00; C07C33/00; C07C33/26; C07C33/28; C07C37/00; C07C37/001; C07C37/01; C07C37/055; C07C39/00; C07C39/12; C07C39/205; C07C39/21; C07C39/24; C07C39/367; C07C39/373; C07C43/00; C07C43/02; C07C43/03; C07C43/14; C07C43/178; C07C43/1782; C07C43/20; C07C43/225; C07C43/23; C07D307/00; C07D307/02; C07D307/04; C07D307/06; C07D307/10; C07D307/12; C07D307/14; C07D309/00; C07D309/02; C07D309/04; C07D309/08; C07D309/10; C07D309/12
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
99 words
A compound of the formula: ##STR51## where n is 0 to 4, R 1 , and R 2 , which can be the same or different, are H or OH, R 3 is --O--(CH 2 ) m --CH 2 --NR 6 R 7 in which m is 1 to 2, R 6 and R 7 , which can be the same or different, are H or an alkyl group of 1 to 4 carbon atoms or --NR 6 R 7 can form a pyrrolidinyl group and R 4 is halogen, or a non-toxic, pharmaceutically acceptable salt or N-oxide thereof.
Claim 2
Dependent Claim
99 words
A compound of the formula: ##STR51## where n is 0 to 4, R 1 , and R 2 , which can be the same or different, are H or OH, R 3 is --O--(CH 2 ) m --CH 2 --NR 6 R 7 in which m is 1 to 2, R 6 and R 7 , which can be the same or different, are H or an alkyl group of 1 to 4 carbon atoms or --NR 6 R 7 can form a pyrrolidinyl group and R 4 is halogen, or a non-toxic, pharmaceutically acceptable salt or N-oxide thereof.
Claim 3
Dependent Claim
41 words
A compound according to claim 1 in which R 6 is CH 3 or C 2 H 5 ; R 7 is H, CH 3 or C 2 H 5 , or NR 6 R 7 together form a pyrrolidinyl group.
Claim 4
Dependent Claim
16 words
A compound according to claim 1 which is 4-chloro-1,2-diphenyl-1-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-butane, (RR,SS), or a non-toxic pharmaceutically acceptable salt.
Claim 5
Dependent Claim
16 words
A compound according to claim 1 which is 4-chloro-1,2-diphenyl-1-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-butane, (RS,SR), or a non-toxic pharmaceutically acceptable salt.
Claim 6
Dependent Claim
36 words
A pharmaceutical composition comprising an amount effective to product an oestrogenic, anti-oestrogenic or progestanic effect, of a compound according to claim 1 or a non-toxic pharmaceutically acceptable salt thereof, and a compatible pharmaceutically acceptable carrier therefor.
Claim 7
Dependent Claim
48 words
A method of producing an oestrogenic, anti-oestrogenic or progestanic effect in a subject in which such an effect is desired which comprises administering to said subject a compound according to claim 1 or a non-toxic pharmaceutically acceptable salt thereof, in an amount sufficient to produce the desired effect.
Claim 8
Dependent Claim
21 words
A method according to claim 6 in which an antioestrogenic effect is produced in a subject suffering from an oestrogen-dependent tumor.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-02-25 | 1994-08-27 | 1995-02-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-02-25 | 1998-08-27 | 1999-02-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-02-25 | 2002-08-27 | 2003-02-26 | $7700.00 | Window Closed / Lapsed |